Suppr超能文献

采用氟达拉滨、美法仑和低剂量抗胸腺细胞球蛋白预处理方案进行挽救性脐血移植的可行性。

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

作者信息

Hoshino Takumi, Takada Satoru, Hatsumi Nahoko, Sakura Toru

机构信息

Leukemia Research Center, Saiseikai Maebashi Hospital, Kamishinden-machi, 564-1, Maebashi, Gunma, 371-0821, Japan.

出版信息

Int J Hematol. 2019 Apr;109(4):463-469. doi: 10.1007/s12185-019-02610-4. Epub 2019 Feb 8.

Abstract

Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT) is a potential re-transplantation option. Total body irradiation (TBI) is often incorporated into the pre-salvage CBT conditioning regimen following PGF; however, patients experiencing PGF are not always amenable to TBI, and non-TBI regimens for salvage CBT should be established. Here, we report five patients with hematologic malignancies who received salvage CBT for PGF following a non-TBI regimen using fludarabine (Flu), melphalan (Mel), and low-dose anti-thymocyte globulin (ATG). The median intervals between the failed allo-SCT and salvage CBT, as well as between the diagnosis of PGF and salvage CBT, were 37 days and 8 days, respectively. The median neutrophil recovery period was 21 days (range 18-21 days). Four of five patients achieved neutrophil engraftment following salvage CBT; all four exhibited sustained engraftment with complete donor chimerism. Three of the five patients were alive after a median follow-up time of 907 days (range 315-909 days) post-salvage CBT; two patients died of causes unrelated to recurrence. These data suggest that CBT following the non-TBI regimen described here is feasible in patients with PGF.

摘要

原发性移植物功能衰竭(PGF)是异基因干细胞移植(allo-SCT)后早期发生的一种致命并发症。脐血移植(CBT)是一种潜在的再次移植选择。全身照射(TBI)通常被纳入PGF后挽救性CBT预处理方案中;然而,发生PGF的患者并不总是适合接受TBI,因此应制定非TBI的挽救性CBT方案。在此,我们报告了5例血液系统恶性肿瘤患者,他们在接受使用氟达拉滨(Flu)、美法仑(Mel)和低剂量抗胸腺细胞球蛋白(ATG)的非TBI方案后,因PGF接受了挽救性CBT。初次allo-SCT失败与挽救性CBT之间以及PGF诊断与挽救性CBT之间的中位间隔分别为37天和8天。中性粒细胞恢复的中位时间为21天(范围18 - 21天)。5例患者中有4例在挽救性CBT后实现了中性粒细胞植入;所有4例均表现为持续植入且完全供体嵌合。5例患者中有3例在挽救性CBT后中位随访907天(范围315 - 909天)后存活;2例患者死于与复发无关的原因。这些数据表明,本文所述的非TBI方案后的CBT对PGF患者是可行的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验